Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 262 Cr.
- Current Price ₹ 166
- High / Low ₹ 242 / 130
- Stock P/E 19.0
- Book Value ₹ 37.0
- Dividend Yield 0.42 %
- ROCE 39.7 %
- ROE 32.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 47.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 52 | 83 | 128 | 163 | 175 | |
| 49 | 78 | 118 | 149 | 157 | |
| Operating Profit | 3 | 5 | 10 | 14 | 19 |
| OPM % | 5% | 6% | 8% | 9% | 11% |
| -0 | 0 | 0 | 1 | 2 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 2 | 3 | 9 | 13 | 19 |
| Tax % | 7% | 27% | 27% | 25% | |
| 1 | 3 | 6 | 10 | 14 | |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 | 8.75 |
| Dividend Payout % | -0% | -0% | 3% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 90% |
| TTM: | 83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| Last Year: | 32% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 42 |
| 8 | 4 | 2 | 6 | 2 | |
| 3 | 8 | 11 | 6 | 11 | |
| Total Liabilities | 12 | 15 | 22 | 64 | 71 |
| 5 | 4 | 8 | 7 | 6 | |
| CWIP | -0 | -0 | -0 | 0 | 1 |
| Investments | 0 | 0 | 0 | -0 | 1 |
| 8 | 11 | 14 | 57 | 63 | |
| Total Assets | 12 | 15 | 22 | 64 | 71 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 7 | -5 | |||
| -3 | -0 | |||
| -3 | 34 | |||
| Net Cash Flow | 2 | 28 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 |
| Inventory Days | 31 | 25 | 23 | 185 |
| Days Payable | 165 | 226 | 237 | 170 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 |
| Working Capital Days | 1 | -14 | -7 | 31 |
| ROCE % | 50% | 98% | 40% |
Documents
Announcements
-
Appointment
5 December 2025 - Ranjeet Kumar Verma regularized as Independent Director; postal ballot approved 04/12/2025; 5-year term; effective 30/10/2025.
-
Shareholders meeting
5 December 2025 - Dec 4, 2025: Postal ballot passed ESOP 2025, extend to group, appoint Ranjeet Verma, vary and extend IPO proceeds utilisation.
-
Appointment
3 December 2025 - Appointed M/s Rawal & Co. as Secretarial Auditor for FY2025-26 on Dec 3, 2025.
-
Appointment
3 December 2025 - Board appointed M/s Rawal & Co. as Secretarial Auditor for FY2025-26 on Dec 03, 2025.
-
Outcome of Board Meeting
3 December 2025 - M/s Rawal & Co appointed secretarial auditor on Dec 03, 2025 for FY2025-26 (one-year term).
Annual reports
Concalls
-
Nov 2025TranscriptPPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.